ArticleBMJ open2026
Access to essential medicines in Albania: a cross-sectional survey of availability, prices and affordability using the WHO/Health Action International (HAI) Global Core List.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the availability, prices and affordability of essential medicines in Albania, focusing on a standardised set of medicines from the Global Core List (GCL), using an adapted WHO/Health Action International (WHO/HAI) methodology.
designCross-sectional survey.
setting30 private community pharmacies across six urban areas in Albania (Tirana, Durrës, Fier, Vlorë, Kavajë and Lushnjë).
participantsLicensed private community pharmacies, including both contracted and non-contracted pharmacies under the national health insurance scheme. OUTCOMES: Availability, patient prices and affordability of 14 medicines from the GCL. Affordability was assessed using the daily wage of the lowest-paid government worker (LPGW), and prices were evaluated using the median price ratio (MPR) compared with international reference prices.
resultsThe mean availability of WHO/HAI GCL medicines was 79.8%, slightly below the WHO target of 80%. In a secondary analysis that included therapeutically equivalent alternative formulations availability increased to 83.3%. Ceftriaxone, amoxicillin and salbutamol were among the least available medicines and were frequently out of stock. All medicines, except ceftriaxone, met affordability criteria based on LPGW. MPR analysis showed that while most medicines were priced competitively, some, including diclofenac and ceftriaxone, were substantially higher than international reference prices, with five medicines exceeding an MPR of 4.0. Overall, 64% of medicines met both availability and affordability thresholds.
conclusionsAccess to essential medicines in Albania appears to be primarily constrained by availability rather than affordability. Gaps in the availability of key antibiotics and asthma medicines highlight the need for targeted policy interventions, including improved procurement, supply chain management and rational use strategies to strengthen equitable access to essential medicines.
Indexed as
Identifiers
42595360What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.